These differences may be explained, at least in part, by structural differences: A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone.
Generate a file for use with external citation management software. Pre-clinical results demonstrated that levofloxacin was 20 times less phototoxic than sparfloxacin and PMS data show that serious phototoxicity develops in only 1 in 1. BMJ ; These side effects can involve the tendons, muscles, joints, nerves, and central nervous system.
Retrieved 7 September Hazell L, Shakir SA. Compared to earlier antibiotics of the fluoroquinoline class such as ciprofloxacinlevofloxacin exhibits greater activity towards Gram-positive bacteria  but lesser activity toward Gram-negative bacteria,  especially Pseudomonas aeruginosa. South Med J ; 99 1: Notably, package inserts for the fluoroquinolones carry warnings regarding use in the elderly, paediatric patients and patients with preexisting, or factors predisposing to, seizure disorders.
JAMA ; Drugs in pregnancy and lactation: Classification and structure-activity relationships of fluoroquinolones. It is a weak inhibitor of CYP2C9 suggesting potential to block the breakdown of warfarin and phenprocoumon.
The higher dose provides greater confidence in treating infections due to organisms for which drug MICs are high or patients with compromised vasculature that limits perfusion of the infection site. Levofloxacinsold under the trade names Levaquin among others, is an antibiotic. A review examining musculoskeletal complications of fluoroquinolones proposed guidelines with respect to administration to athletes, that called for avoiding all use of fluoroquinolone antibiotics if possible, and if they are used: Ann Noninvasive Electrocardiol ; 11 1: Katsuro Yagawa Daiichi Pharmaceutical Co.
Safety and tolerability profile of moxifloxacin MXF [abstract P]. Creatinine clearance CL cr was calculated by the Cockcroft and Gault method 4 using the baseline serum creatinine value of the subject and was employed as an index of each subject's renal function.
In the present study, the variation in pharmacokinetic parameters appeared to be related to renal function and body weight.
In addition, blood samples were obtained immediately prior to dosing on days 5 through 9. Subjects were judged healthy on the basis of normal findings on medical history, physical examination, clinical laboratory tests, and electrocardiography ECG. Archived from the original on 25 February